Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de...
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma...
SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today jointly announced with Eli Lilly and Company ("Lilly", NYSE: LLY) the final clinical outcome and biomarker analysis of the...
Swiss Pharma Company – IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)
HURDEN, Switzerland, Jan. 22, 2022 /PRNewswire/ -- IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood cancer called peripheral T-cell lymphoma (PTCL) that relapsed...
China Jo-Jo Drugstores Reports First Half of Fiscal Year 2022 Financial Results
HANGZHOU, China, Jan. 21, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products, and healthcare provider in China, today announced its financial results for the first half of fiscal year 2022 ended September 30, 2021. Mr. Lei Liu, Chairman...
Happiness Development Announces $10 Million Private Placement to Support Its International Expansion
NANPING, China, Jan. 21, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) a China-based company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce sales and e-commerce marketing solutions, and the sales of automobile today announced it has entered into certain securities purchase agreement with several non-U.S. strategic investors to sell total 12,500,000...
Ashraya Foundation Signs 60 Crore INR Agreement with Edufront Technologies
NEW DELHI, Jan. 21, 2022 /PRNewswire/ -- Ashraya, a non-profit society founded in 1997 to give aid to development projects in education and healthcare for the underprivileged, has entered into an agreement with Edufront Technologies Private Limited whereby Ashraya will support 10,000 students using Edufront's technology and model for the next...
ELEVAI LABS, INC. ANNOUNCES GLOBAL DISTRIBUTION PARTNERSHIP WITH PREMIER AESTHETIC DEVICE COMPANY DERMAPENWORLD
DAVIS, Calif., Jan. 21, 2022 /PRNewswire/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that it has signed a non-exclusive global distributor and trademark license agreement with leading Australian headquartered aesthetic device...
Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.
Enter the Huge Blue Ocean of Synthetic Biology in Advance Improve Product Matrix in Medical Aesthetics Field HONG KONG, Jan. 21, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce that Beijing MeiYan KongJian...
ESTA Lunar New Year with UltraBactech, proven to target and kill 99.999% of the SARS-CoV-2 virus, presents the new Spring collection design & gift sets
ESTA Technology Pte Ltd is the first company in Singapore, to design Plant Base hand sanitisers, hand soaps to surface disinfectants for the family. This Lunar New Year, be with ESTA "CNY Nature Guard Box" and "CNY VTL Travel Pouch" to bring joy, prosperity, and good health to your loved ones and friends. SINGAPORE, Jan. 21, 2022 /PRNewswire/...
Suvoda Exceeds 2021 Targets; Poised for Continued Growth Supporting Complex Clinical Trials in 2022
Surpasses 900 trials across 65 countries, expands leadership team and product offerings, and posts another year of 30% growth, all while maintaining an exceptional performance level. PHILADELPHIA, Jan. 20, 2022 /PRNewswire/ -- Suvoda, LLC, a global clinical trial technology company that specializes in highly complex studies, such as oncology, central nervous system...
